Yukimasa Hatachi
Overview
Explore the profile of Yukimasa Hatachi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
515
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ogata M, Satake H, Ogata T, Hatachi Y, Hara S, Hirota S, et al.
Intern Med
. 2019 Jul;
58(22):3243-3246.
PMID: 31327822
We herein report the first case in which an escalated dose of sunitinib was effective, even after dose reduction. A 64-year-old man with gastrointestinal stromal tumor of the small intestine...
12.
Moriwaki T, Sakai Y, Ishida H, Yamamoto Y, Endo S, Kuramochi H, et al.
Int J Clin Oncol
. 2019 May;
24(10):1214-1222.
PMID: 31089842
Background: Alternate-day administration of S-1 is thought to reduce toxicities. This phase II study evaluated S-1 on alternate days combined with bevacizumab as first-line treatment for elderly patients with metastatic...
13.
Ogata T, Satake H, Ogata M, Hatachi Y, Maruoka H, Yamashita D, et al.
Oncotarget
. 2019 Feb;
10(10):1070-1084.
PMID: 30800219
Introduction: FOLFOXIRI plus bevacizumab has a promising efficacy as first-line systemic chemotherapy for metastatic colorectal cancer (mCRC). This study aimed to evaluate the safety and effectiveness of FOLFOXIRI plus antibodies....
14.
Ogata T, Kikawa Y, Ogata M, Satake H, Hatachi Y, Yasui H
Case Rep Oncol
. 2018 Nov;
11(3):699-704.
PMID: 30483101
Diffuse liver metastasis is a rare pattern of liver metastasis that is associated with hepatic failure and poor prognosis. We experienced 2 cases of acute liver failure due to diffuse...
15.
Ogata M, Hatachi Y, Ogata T, Satake H, Imai Y, Yasui H
Intern Med
. 2018 Nov;
58(7):1029-1032.
PMID: 30449794
Inflammatory myofibroblastic tumor (IMT), a rare sarcoma, is primarily treated via resection of the mass. However, in cases of recurrence or unresectable tumors, no standard care exists. While crizotinib, an...
16.
Ogata T, Satake H, Ogata M, Hatachi Y, Inoue K, Hamada M, et al.
Oncotarget
. 2018 Oct;
9(77):34520-34527.
PMID: 30349646
Introduction: The neutrophil-to-lymphocyte ratio (NLR) is effective as a predictive factor for lung cancer treated with nivolumab. The objective of this study was to determine the effectiveness of NLR for...
17.
Kikawa Y, Hatachi Y, Rumpold G, Tokiwa M, Takebe S, Ogata T, et al.
Breast Cancer
. 2018 Sep;
26(2):255-259.
PMID: 30194662
Background: The main purposes of metastatic breast cancer (MBC) treatment are to prolong survival and maintain health-related quality of life (HRQOL). Compliance with the HRQOL assessment can be poor, particularly...
18.
Satake H, Sagawa T, Fujikawa K, Hatachi Y, Yasui H, Kotaka M, et al.
Cancer Chemother Pharmacol
. 2018 Sep;
82(5):839-845.
PMID: 30167847
Purpose: Optimal salvage chemotherapy for patients with treated advanced/metastatic gastric cancer (AGC) is unknown. Irinotecan is commonly used in Japan. Ramucirumab, a human IgG-1 monoclonal antibody targeting the extracellular domain...
19.
Kotake T, Satake H, Okita Y, Hatachi Y, Hamada M, Omiya M, et al.
Asia Pac J Clin Oncol
. 2018 Jul;
15(1):63-68.
PMID: 29984542
Background: Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown. Aim: To evaluate the prevalence and risk...
20.
Ogata T, Satake H, Ogata M, Hatachi Y, Yasui H
Case Rep Oncol
. 2018 Apr;
11(1):143-150.
PMID: 29681813
Following the ATTRACTION-2 study, nivolumab was approved for advanced gastric cancer in Japan. However, pseudoprogression and hyperprogressive disease have been reported in patients treated with immune checkpoint inhibitors. We report...